RADNOR, Pa.--(BUSINESS WIRE)--PolyMedix, Inc. (OTC BB: PYMX, http://polymedix.com), an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and patients with acute cardiovascular disorders, announced today the pricing of an underwritten offering of 25 million units, each unit consisting of one share of its common stock and a warrant to purchase one-half of a share of its common stock at an offering price of $0.80 per unit. PolyMedix expects to receive net proceeds, after deducting the underwriting discount and estimated offering expenses, of approximately $18.6 million. The warrants will have a five-year term and an exercise price equal to $0.80 per share.
